BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antitope and Eden Biodesign Enter Into a Research Agreement


2/6/2013 10:35:26 AM

Cambridge UK, February 2013 - Antitope Ltd. (UK) today announced a Research Agreement with Eden Biodesign Ltd. (Liverpool, UK) for the development of therapeutic antibodies. As part of the Agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding mammalian cell line for manufacture of the therapeutic.

Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope commented, "We are very pleased to work with Eden Biodesign and assist in the development of their antibody therapeutics. The partnership combines Antitope's core technologies in the generation of high-yielding manufacturing cell lines for the production of therapeutic antibodies with Eden Biodesign’s extensive experience in biopharmaceutical discovery, process development and GMP manufacturing."

Dr Crawford Brown, Chief Executive Officer of Eden Biodesign, Ltd., a member of the Watson Group, added: “After a careful and diligent search for a partner capable of both meeting our exacting quality standards and delivering highly productive and compliant cGMP production cell lines, we are very happy to be working with Antitope on this important project.”

About Antitope

Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in the generation of humanised antibodies devoid of T cell epitopes. Antitope's proprietary Composite CHO™ and cell line development technologies result in the generation of high yielding manufacturing cell lines suitable for transfer to CMOs and GMP manufacturing. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For more information, please visit www.antitope.co.uk or contact:

Antitope Ltd.

Dr Neil Butt, Business Development Director

Tel: +44 (0)1223 496190

Email: info@antitope.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES